November 10, 2026
The National Social Security Fund announced a package of new measures aimed at expanding the scope of health coverage and reducing the financial burdens on those insured, which included raising the contribution rate for myasthenia gravis medications, doubling the tariff for textile work, and including the specialty of preterm infants and newborns in the approved list.
In a statement issued by the Directorate of Public Relations, the Director General of Insurance, Muhammad Karaki, issued on November 10, 2026, three information memos bearing the numbers 854, 855, and 856. This step comes in the context of the ongoing development and modernization workshop led by Karaki in cooperation with the Chairman of the Board of Directors, Bishara Al-Asmar, and with the support of the Minister of Labor, Muhammad Haider, with the aim of simplifying procedures and improving the level of hospital and medical services.
In the details of the memorandums, Memorandum No. 854 stipulated raising the fund’s contribution to the costs of myasthenia gravis medications from 80% to 95%, to include treatments inside and outside hospitals. This amendment comes based on Decree No. 4229 issued on October 30, 2026 and published in the Official Gazette (Issue 48) on November 5, 2026, and it will come into force as of the date of publication.
For its part, Memorandum No. 855 stipulated the addition of the specialty of preterm infants and newborns and determining the value of medical examinations throughout the treatment period, based on Board of Directors Resolution No. 33 issued on October 22, 2026, coupled with the approval of the guardianship authority No. 126/1 on November 4, 2026.
In the same context, Memorandum No. 856 stipulated raising the tariff for histology work (A-Pathology) to four times its previous value, with half the value of the tariff (A) allocated to the histology doctor, based on Board of Directors Resolution No. 32 dated October 22, 2026, approved by the guardianship authority No. 124/1 on November 4, 2026.
These decisions coincide with the project to adopt drug pricing based on the intermediate price approaching its final stages, in addition to the ongoing efforts to amend the tariffs for medical and hospital work, especially the most in-demand services within hospitals such as surgical operations.
Director General Muhammad Karaki stressed that these measures are of great importance at the health and social levels. Due to its support for delicate medical conditions that require extreme medical care, considering it a pivotal pillar for developing health services and enhancing their comprehensiveness, integration and fairness.
The Fund concluded by emphasizing that it will move forward in taking all measures to improve the level of health and social benefits for the insured, in a way that contributes to alleviating the burden of living imposed on them under the current circumstances.
